Unlocking New Avenues in Breast Cancer Treatment: The Synergy of Kinase Inhibitors and Immunotherapy

• Published in: Cancers Vol. 15; no. 23; p. 5499
• Main Authors: Bravo, María José, Burgos-Molina, Antonio Manuel, García-Aranda, Marilina, Redondo, Maximino, Téllez, Teresa
• Format: Journal Article
• Language: English
• Published: Switzerland MDPI AG 21.11.2023
• Subjects: antibody monoclonal; Breast cancer; Cancer; Cancer therapies; Care and treatment; Cell activation; Cell growth; combination therapies; Development and progression; Enzyme inhibitors; Immune checkpoint inhibitors; Immunotherapy; inhibitor; Kinases; Lung cancer; Medical research; Medicine, Experimental; Metastases; Mortality; protein kinase; Protein kinase inhibitors; Protein kinases; Tumor cells; Tumor microenvironment; Tumors; Spain; breast cancer; inhibitor; combination therapies; antibody monoclonal; protein kinase; immunotherapy
• ISSN: 2072-6694; 2072-6694
• DOI: 10.3390/cancers15235499

Cancer is one of the world's most significant health problems today. Currently, breast cancer has globally surpassed lung cancer as the most commonly diagnosed cancer in women. In 2020, an estimated 2,261,419 new cases were diagnosed in women worldwide. Therefore, there is a need to understand the processes that can help us better treat this disease. In recent years, research in the fight against cancer has often been based on two treatment modalities. One of them is the use of protein kinase inhibitors, which have been instrumental in the development of new therapeutic strategies. Another crucial route is the use of immunotherapy, which has been touted as a great promise for cancer treatment. Protein kinase alterations can interfere with the effectiveness of other treatments, such as immunotherapy. In this review, we will analyze the role played by protein kinase alterations in breast cancer and their possible impact on the effectiveness of the response to immunotherapy treatments.